News &amp; Updates

Once-weekly, subcutaneous mazdutide treatment yields meaningful reduction in bodyweight in a US cohort of adults with obesity or overweight, according to a phase II study.

Mazdutide demonstrates weight-loss benefit in US cohort

Original New Drug Application Approvals by US FDA (1-15 December 2025)

New drug applications approved by US FDA as of 1-15 December 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 December 2025)

Original New Drug Application Approvals by US FDA (1-15 August 2026)

New drug applications approved by US FDA as of 1-15 August 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 August 2026)

Continuous clozapine use may reduce suicide deaths in schizophrenia

Continued treatment with clozapine has been associated with a lower the risk of suicide mortality among patients with schizophrenia in Hong Kong.

Continuous clozapine use may reduce suicide deaths in schizophrenia

NSAID use lowers risk of developing AMD

Patients prescribed NSAIDs appear protected against the development of age-related macular degeneration (AMD) compared with nonusers, suggests a study.

NSAID use lowers risk of developing AMD

Vedolizumab, ustekinumab both safe, effective in biologic-naïve CD patients

The effectiveness, safety, and healthcare resource utilization outcomes during the 36-month treatment period are similar across biologic-naïve patients with Crohn’s disease (CD), regardless of baseline disease location, according to a study.

Vedolizumab, ustekinumab both safe, effective in biologic-naïve CD patients

Semaglutide works wonders in MASH, MASLD

Use of semaglutide results in steatohepatitis resolution and improved biochemical and imaging markers among patients with metabolic dysfunction-associated steatotic liver disease (MASLD), results of a meta-analysis have shown.

Semaglutide works wonders in MASH, MASLD

Almond-based low carb diet improves nocturnal glycaemic control in T2D

In patients with type 2 diabetes (T2D), following an almond-based low-carbohydrate diet (LCD) helps optimize nighttime time-in-range metrics, according to a study.

Almond-based low carb diet improves nocturnal glycaemic control in T2D

More migraine-free days with rimegepant

The CGRP* receptor antagonist rimegepant provides consistent pain relief and improves function in patients with migraine, as shown in the CONFIDENCE trial presented at EAN 2026.

More migraine-free days with rimegepant

Extremes in BMI linked to poor pregnancy outcomes in ART

At the high and low extremes, BMI is associated with increased early miscarriage and reduced pregnancy success among patients undergoing assisted reproductive technology (ART), according to data presented at ESHRE 2026.

Extremes in BMI linked to poor pregnancy outcomes in ART